5UDD image
Deposition Date 2016-12-26
Release Date 2017-05-17
Last Version Date 2024-11-20
Entry Detail
PDB ID:
5UDD
Title:
Crystal Structure of RSV F B9320 Bound to MEDI8897
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
4.30 Å
R-Value Free:
0.29
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
P 32 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Fusion glycoprotein F0
Mutations:S155C, S290C, S190F, V207L
Chain IDs:A, B, C, D, E, F, G, H, I
Chain Length:568
Number of Molecules:9
Biological Source:Human Respiratory syncytial virus 9320
Polymer Type:polypeptide(L)
Molecule:MEDI8897 Fab Heavy Chain
Chain IDs:J, K, L, M, N, O
Chain Length:228
Number of Molecules:6
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:MEDI8897 Fab Light Chain
Chain IDs:P, Q, R, S, T, U
Chain Length:214
Number of Molecules:6
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
Sci Transl Med 9 ? ? (2017)
PMID: 28469033 DOI: 10.1126/scitranslmed.aaj1928

Abstact

Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health priority. However, no vaccine is currently available to protect this vulnerable population. Palivizumab, the only approved agent for RSV prophylaxis, is limited to high-risk infants, and the cost associated with the requirement for dosing throughout the RSV season makes its use impractical for all infants. We describe the development of a monoclonal antibody as potential RSV prophylaxis for all infants with a single intramuscular dose. MEDI8897*, a highly potent human antibody, was optimized from antibody D25, which targets the prefusion conformation of the RSV fusion (F) protein. Crystallographic analysis of Fab in complex with RSV F from subtypes A and B reveals that MEDI8897* binds a highly conserved epitope. MEDI8897* neutralizes a diverse panel of RSV A and B strains with >50-fold higher activity than palivizumab. At similar serum concentrations, prophylactic administration of MEDI8897* was ninefold more potent than palivizumab at reducing pulmonary viral loads by >3 logs in cotton rats infected with either RSV A or B subtypes. MEDI8897 was generated by the introduction of triple amino acid substitutions (YTE) into the Fc domain of MEDI8897*, which led to more than threefold increased half-life in cynomolgus monkeys compared to non-YTE antibody. Considering the pharmacokinetics of palivizumab in infants, which necessitates five monthly doses for protection during an RSV season, the high potency and extended half-life of MEDI8897 support its development as a cost-effective option to protect all infants from RSV disease with once-per-RSV-season dosing in the clinic.

Legend

Protein

Chemical

Disease

Primary Citation of related structures